
    
      It's a single center, single arm, prospective clinical trial. Patients younger than 65 years
      old with primary central nervous system lymphoma will received four cycles of chemotherapy
      with rituximab plus high-dose methotrexate and temozolomide as induction therapy, and then
      received consolidation therapy with autologous stem cell transplant for which the
      conditioning regimen is Carmustine plus thiotepa.
    
  